Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

Sunanda J. Chatterjee, Ram Datar, David Youssefzadeh, Ben George, Peter J. Goebell, John P. Stein, Lillian Young, Shan Rong Shi, Conway Gee, Susan Groshen, Donald G. Skinner, Richard J Cote

Research output: Contribution to journalArticle

218 Citations (Scopus)

Abstract

Purpose: To determine the combined effects of p53, p21, and pRb alterations in predicting the progression of bladder transitional cell carcinoma. Patients and Methods: p53, p21, and pRb expression was examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node-negative, 117 patients; lymph node-positive, 47 patients). Median follow-up was 8.6 years. Based on percentage of nuclear reactivity, p53 was considered as wild-type (0% to 10%) or altered (> 10%); p21 was scored as wild-type (> 10%) or altered (< 10%); and pRb status was considered wild-type (1% to 50%) or altered (0% or > 50%). Results: As individual determinants, the p53, p21, and pRb status were independent predictors of time to recurrence (P < .001, P < .001, and P < .001, respectively), and overall survival (P < .001, P = .002, and P = .001, respectively). By examining these determinants in combination, patients were categorized as group I (no alteration in any determinant, 47 patients), group II (any one determinant altered, 51 patients), group III (any two determinants altered, 42 patients), and group IV (all three determinants altered, 24 patients). The 5-year recurrence rates in these groups were 23%, 32%, 57%, and 93%, respectively (log-rank P < .001), and the 5-year survival rates were 70%, 58%, 33%, and 8%, respectively (log-rank P < .001). After stratifying by stage, the number of altered proteins remained significantly associated with time to recurrence and overall survival. Conclusion: This study suggests that alterations in p53, p21, and pRb act in cooperative or synergistic ways to promote bladder cancer progression. Examining these determinants in combination provides additional information above the use of a single determinant alone.

Original languageEnglish
Pages (from-to)1007-1013
Number of pages7
JournalJournal of Clinical Oncology
Volume22
Issue number6
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Urinary Bladder
Recurrence
Lymph Nodes
Survival
Cystectomy
Urinary Bladder Neoplasms
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. / Chatterjee, Sunanda J.; Datar, Ram; Youssefzadeh, David; George, Ben; Goebell, Peter J.; Stein, John P.; Young, Lillian; Shi, Shan Rong; Gee, Conway; Groshen, Susan; Skinner, Donald G.; Cote, Richard J.

In: Journal of Clinical Oncology, Vol. 22, No. 6, 01.12.2004, p. 1007-1013.

Research output: Contribution to journalArticle

Chatterjee, SJ, Datar, R, Youssefzadeh, D, George, B, Goebell, PJ, Stein, JP, Young, L, Shi, SR, Gee, C, Groshen, S, Skinner, DG & Cote, RJ 2004, 'Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma', Journal of Clinical Oncology, vol. 22, no. 6, pp. 1007-1013. https://doi.org/10.1200/JCO.2004.05.174
Chatterjee, Sunanda J. ; Datar, Ram ; Youssefzadeh, David ; George, Ben ; Goebell, Peter J. ; Stein, John P. ; Young, Lillian ; Shi, Shan Rong ; Gee, Conway ; Groshen, Susan ; Skinner, Donald G. ; Cote, Richard J. / Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 6. pp. 1007-1013.
@article{b608b54db3f845ce98b78fa2c21a1551,
title = "Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma",
abstract = "Purpose: To determine the combined effects of p53, p21, and pRb alterations in predicting the progression of bladder transitional cell carcinoma. Patients and Methods: p53, p21, and pRb expression was examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node-negative, 117 patients; lymph node-positive, 47 patients). Median follow-up was 8.6 years. Based on percentage of nuclear reactivity, p53 was considered as wild-type (0{\%} to 10{\%}) or altered (> 10{\%}); p21 was scored as wild-type (> 10{\%}) or altered (< 10{\%}); and pRb status was considered wild-type (1{\%} to 50{\%}) or altered (0{\%} or > 50{\%}). Results: As individual determinants, the p53, p21, and pRb status were independent predictors of time to recurrence (P < .001, P < .001, and P < .001, respectively), and overall survival (P < .001, P = .002, and P = .001, respectively). By examining these determinants in combination, patients were categorized as group I (no alteration in any determinant, 47 patients), group II (any one determinant altered, 51 patients), group III (any two determinants altered, 42 patients), and group IV (all three determinants altered, 24 patients). The 5-year recurrence rates in these groups were 23{\%}, 32{\%}, 57{\%}, and 93{\%}, respectively (log-rank P < .001), and the 5-year survival rates were 70{\%}, 58{\%}, 33{\%}, and 8{\%}, respectively (log-rank P < .001). After stratifying by stage, the number of altered proteins remained significantly associated with time to recurrence and overall survival. Conclusion: This study suggests that alterations in p53, p21, and pRb act in cooperative or synergistic ways to promote bladder cancer progression. Examining these determinants in combination provides additional information above the use of a single determinant alone.",
author = "Chatterjee, {Sunanda J.} and Ram Datar and David Youssefzadeh and Ben George and Goebell, {Peter J.} and Stein, {John P.} and Lillian Young and Shi, {Shan Rong} and Conway Gee and Susan Groshen and Skinner, {Donald G.} and Cote, {Richard J}",
year = "2004",
month = "12",
day = "1",
doi = "10.1200/JCO.2004.05.174",
language = "English",
volume = "22",
pages = "1007--1013",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

AU - Chatterjee, Sunanda J.

AU - Datar, Ram

AU - Youssefzadeh, David

AU - George, Ben

AU - Goebell, Peter J.

AU - Stein, John P.

AU - Young, Lillian

AU - Shi, Shan Rong

AU - Gee, Conway

AU - Groshen, Susan

AU - Skinner, Donald G.

AU - Cote, Richard J

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Purpose: To determine the combined effects of p53, p21, and pRb alterations in predicting the progression of bladder transitional cell carcinoma. Patients and Methods: p53, p21, and pRb expression was examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node-negative, 117 patients; lymph node-positive, 47 patients). Median follow-up was 8.6 years. Based on percentage of nuclear reactivity, p53 was considered as wild-type (0% to 10%) or altered (> 10%); p21 was scored as wild-type (> 10%) or altered (< 10%); and pRb status was considered wild-type (1% to 50%) or altered (0% or > 50%). Results: As individual determinants, the p53, p21, and pRb status were independent predictors of time to recurrence (P < .001, P < .001, and P < .001, respectively), and overall survival (P < .001, P = .002, and P = .001, respectively). By examining these determinants in combination, patients were categorized as group I (no alteration in any determinant, 47 patients), group II (any one determinant altered, 51 patients), group III (any two determinants altered, 42 patients), and group IV (all three determinants altered, 24 patients). The 5-year recurrence rates in these groups were 23%, 32%, 57%, and 93%, respectively (log-rank P < .001), and the 5-year survival rates were 70%, 58%, 33%, and 8%, respectively (log-rank P < .001). After stratifying by stage, the number of altered proteins remained significantly associated with time to recurrence and overall survival. Conclusion: This study suggests that alterations in p53, p21, and pRb act in cooperative or synergistic ways to promote bladder cancer progression. Examining these determinants in combination provides additional information above the use of a single determinant alone.

AB - Purpose: To determine the combined effects of p53, p21, and pRb alterations in predicting the progression of bladder transitional cell carcinoma. Patients and Methods: p53, p21, and pRb expression was examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node-negative, 117 patients; lymph node-positive, 47 patients). Median follow-up was 8.6 years. Based on percentage of nuclear reactivity, p53 was considered as wild-type (0% to 10%) or altered (> 10%); p21 was scored as wild-type (> 10%) or altered (< 10%); and pRb status was considered wild-type (1% to 50%) or altered (0% or > 50%). Results: As individual determinants, the p53, p21, and pRb status were independent predictors of time to recurrence (P < .001, P < .001, and P < .001, respectively), and overall survival (P < .001, P = .002, and P = .001, respectively). By examining these determinants in combination, patients were categorized as group I (no alteration in any determinant, 47 patients), group II (any one determinant altered, 51 patients), group III (any two determinants altered, 42 patients), and group IV (all three determinants altered, 24 patients). The 5-year recurrence rates in these groups were 23%, 32%, 57%, and 93%, respectively (log-rank P < .001), and the 5-year survival rates were 70%, 58%, 33%, and 8%, respectively (log-rank P < .001). After stratifying by stage, the number of altered proteins remained significantly associated with time to recurrence and overall survival. Conclusion: This study suggests that alterations in p53, p21, and pRb act in cooperative or synergistic ways to promote bladder cancer progression. Examining these determinants in combination provides additional information above the use of a single determinant alone.

UR - http://www.scopus.com/inward/record.url?scp=1842509884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842509884&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.05.174

DO - 10.1200/JCO.2004.05.174

M3 - Article

C2 - 14981105

AN - SCOPUS:1842509884

VL - 22

SP - 1007

EP - 1013

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -